Skip to main content
SpringerLink
Log in

Nephrogene systemische Fibrose (NSF): Wie hoch ist das Risiko und wie können wir es vermeiden?

Nephrogenic systemic fibrosis: what is the risk and how to prevent it?

  • Leitthema
  • Published:
Gefässchirurgie Aims and scope Submit manuscript

Zusammenfassung

Das Krankheitsbild der nephrogenen systemischen Fibrose, das nach Durchführung einer Gadolinium unterstützen Magnetresonanztomographie/-angiographie bei Patienten mit schwerer Niereninsuffizienz auftreten kann, hat zu einer massiven Verunsicherung in der Anwendung dieser wertvollen Untersuchungstechnik geführt. Das Ziel der vorliegenden Arbeit ist es, neben der Diskussion des Krankheitskonzepts, der zugrundeliegenden Pathophysiologie, der Klinik und der therapeutischen Optionen, die Risikofaktoren zu beleuchten und Konzepte der Prävention aufzuzeigen.

Abstract

Nephrogenic systemic fibrosis is a severe systemic disease which can occur in patients with severe chronic kidney disease or acute kidney injury after the administration of gadolinium-based contrast agents. This observation led to a great uncertainty in the use of gadolinium-enhanced magnetic resonance imaging techniques. The purpose of this review is to discuss the concept of the disease, the clinical aspects, prognosis and therapeutic options. In particular, the risk factors involved are emphasized and preventive measures presented.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Abb. 1
Abb. 2
Abb. 3
Abb. 4
Abb. 5

Literatur

  1. Anonymous (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39(2 Suppl 1):S 1–S 266

    Google Scholar 

  2. Bongartz G, Weishaupt D, Mayr M (2008) Neue Kontrastmittelproblematik bei Niereninsuffizienz: Gadolinium-induzierte Nephrogene Systemische Fibrose (NSF). Schweiz Med Forum 8:116–123

    Google Scholar 

  3. Braverman IM, Cowper S (2010) Nephrogenic systemic fibrosis. F1000 Med Rep 2:84

    Article  PubMed  Google Scholar 

  4. Cowper SE, Robin HS, Steinberg SM et al (2000) Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 356:1000–1001

    Article  PubMed  CAS  Google Scholar 

  5. Cowper SE, Su LD, Bhawan J et al (2001) Nephrogenic fibrosing dermopathy. Am J Dermatopathol 23:383–393

    Article  PubMed  CAS  Google Scholar 

  6. Cowper SE (2005) Nephrogenic systemic fibrosis: the nosological and conceptual evolution of nephrogenic fibrosing dermopathy. Am J Kidney Dis 46:763–765

    Article  PubMed  Google Scholar 

  7. Cowper SE Nephrogenic Fibrosing Dermopathy [ICNSFR Website]. 2001–2009. Available at http://www.icnsfr.org. Zugegriffen: 25. Juni 2011

  8. Cuffy MC, Singh M, Formica R et al (2011) Renal transplantation for nephrogenic systemic fibrosis: a case report and review of the literature. Nephrol Dial Transplant 26:1099–1101

    Article  PubMed  Google Scholar 

  9. European Medicines Agency (2011) http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2009/11/WC500015569.pdf. Accessed 25.06.11

  10. Grobner T (2006) Gadolinium – a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 21:1104–1108

    Article  PubMed  CAS  Google Scholar 

  11. Grobner T (2006) Gadolinium – a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? [erratum]. Nephrol Dial Transplant 21:1745

    Article  CAS  Google Scholar 

  12. High WA, Ayers RA, Cowper SEJ (2007) Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 56:710–712

    Article  PubMed  Google Scholar 

  13. Joffe P, Thomsen HS, Meusel M (1998) Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acad Radiol 5:491–502

    Article  PubMed  CAS  Google Scholar 

  14. Ledneva E, Karie S, Launay-Vacher V et al (2009) Renal safety of gadolinium-based contrast media in patients with chronic renal insufficiency. Radiology 250:618–628

    Article  PubMed  Google Scholar 

  15. Leiner T, Kucharczyk W (2009) NSF prevention in clinical practice: summary of recommendations and guidelines in the United States, Canada, and Europe. J Magn Reson Imaging 30:1357–1363

    Article  PubMed  Google Scholar 

  16. Leung N, Shaikh A, Cosio FG et al (2010) The outcome of patients with nephrogenic systemic fibrosis after successful kidney transplantation. Am J Transplant 10:558–562

    Article  PubMed  CAS  Google Scholar 

  17. Marckmann P, Skov L, Rossen K et al (2006) Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 17:2359–2362

    Article  PubMed  Google Scholar 

  18. Martin DR, Semelka RC, Chapman A et al (2009) Nephrogenic systemic fibrosis versus contrast-induced nephropathy: risks and benefits of contrast-enhanced MR and CT in renally impaired patients. J Magn Reson Imaging 30:1350–1356

    Article  PubMed  Google Scholar 

  19. Mayr M, Burkhalter F, Bongartz G (2009) Nephrogenic systemic fibrosis: clinical spectrum of disease. J Magn Reson Imaging 30:1289–1297

    Article  PubMed  Google Scholar 

  20. National Kidney Foundation. Calculators for Health Care Professionals. http://www.kidney.org/professionals/kdoqi/gfr_calculator.cfm

  21. Newton BB, Jimenez SA (2009) Mechanism of NSF: New evidence challenging the prevailing theory. J Magn Reson Imaging 30:1277–1283

    Article  PubMed  Google Scholar 

  22. Panesar M, Banerjee S, Barone GW (2008) Clinical improvement of nephrogenic systemic fibrosis after kidney transplantation. Clin Transplant 22:803–808

    Article  PubMed  Google Scholar 

  23. Perazella MA (2007) Nephrogenic systemic fibrosis, kidney disease, and gadolinium: is there a link? Clin J Am Soc Nephrol 2:200–202

    Article  PubMed  CAS  Google Scholar 

  24. Prince MR, Zhang HL, Roditi GH et al (2009) Risk factors for NSF: a literature review. J Magn Reson Imaging 30:1298–1308

    Article  PubMed  Google Scholar 

  25. Prince MR, Zhang H, Zou Z et al (2011) Incidence of immediate gadolinium contrast media reactions. AJR Am J Roentgenol 196:W138–W143

    Article  PubMed  Google Scholar 

  26. Roditi G, Maki JH, Oliveira GJ et al (2009) Renovascular imaging in the NSF Era. Magn Reson Imaging 30:1323–1334

    Article  Google Scholar 

  27. Sherry AD, Caravan P, Lenkinski RE (2009) Primer on gadolinium chemistry. J Magn Reson Imaging 30:1240–1248

    Article  PubMed  Google Scholar 

  28. Sieber MA, Steger-Hartmann T, Lengsfeld P et al (2009) Gadolinium-based contrast agents and NSF: evidence from animal experience. J Magn Reson Imaging 30:1268–1276

    Article  PubMed  Google Scholar 

  29. Swaminathan S, Shah SV (2007) New insights into nephrogenic systemic fibrosis. J Am Soc Nephrol 18:2636–2643

    Article  PubMed  CAS  Google Scholar 

  30. U.S. Food and Drug Administration. Available at http://www.fda.gov/cder/drug/advisory/gadolinium_agents.htm. Accessed 25.06.11

  31. Wang Y, Alkasab TK, Narin O et al (2011) Incidence of Nephrogenic Systemic Fibrosis after Adoption of Restrictive Gadolinium-based Contrast Agent Guidelines. Radiology 260:105–111

    Article  PubMed  Google Scholar 

  32. Weinreb JC, Abu-Alfa AKJ (2009) Gadolinium-based contrast agents and nephrogenic systemic fibrosis: why did it happen and what have we learned? Magn Reson Imaging 30:1236–1239

    Article  Google Scholar 

Download references

Interessenskonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

  1. Medizinische Poliklinik, Universitätsspital Basel, Petersgraben 4, 4031, Basel, Schweiz

    M. Mayr MD

  2. Institut für Radiologie, Universitätsspital Basel, Basel, Schweiz

    G. Bongartz

Authors
  1. M. Mayr MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Bongartz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Mayr MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mayr, M., Bongartz, G. Nephrogene systemische Fibrose (NSF): Wie hoch ist das Risiko und wie können wir es vermeiden?. Gefässchirurgie 16, 462–468 (2011). https://doi.org/10.1007/s00772-011-0889-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00772-011-0889-z

Schlüsselwörter

Keywords

Search

Navigation